Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 12/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.64 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.64 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413193 | 0.92 | PDE10A (0.63) | PDE10APDE3APDE3BKITACHE | |
| SCHEMBL4403831 | 0.90 | PDE10A (0.67) | PDE10APDE3APDE3BKITACHE | |
| SCHEMBL4402616 | 0.87 | PDE10A (0.61) | PDE10APDE3APDE3BKITACHE | |
| SCHEMBL5501238 | 0.87 | PDE10A (0.63) | PDE10APDE3APDE3BKITACHE | |
| SCHEMBL5994058 | 0.86 | PDE10A (0.72) | PDE10APDE3APDE3BKITACHE | |
| SCHEMBL4397080 | 0.85 | PDE10A (0.65) | PDE10APDE3APDE3BKITACHE | |
| SCHEMBL5513778 | 0.85 | PDE10A (0.69) | PDE10APDE3APDE3BKITACHE | |
| SCHEMBL4397682 | 0.85 | PDE10A (0.69) | PDE10APDE3APDE3BKITACHE | |
| SCHEMBL4411881 | 0.84 | PDE10A (0.66) | PDE10APDE3APDE3BKITACHE | |
| SCHEMBL4397514 | 0.84 | PDE10A (0.47) | PDE10APDE3APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838702-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Pfizer Products Inc. (US) | 2007-10-03 | — | — | EP | claimed |
| US-20060183763-A1 | Novel pyrrolidyl derivatives of heteroaromatic compounds | PFIZER INC | 2006-08-17 | — | — | US | claimed |
| WO-2006070284-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-06 | — | — | WO | claimed |
| US-10039764-B2 | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression | UNIVERSITY OF SOUTH ALABAMA (US) | 2018-08-07 | — | — | US | disclosed |
| US-20160143912-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | UNIVERSITY OF SOUTH ALABAMA (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2015006689-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | UNIVERSITY OF SOUTH ALABAMA (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-1838702-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Pfizer Products Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1755611-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060183763-A1 | Novel pyrrolidyl derivatives of heteroaromatic compounds | PFIZER INC | 2006-08-17 | — | — | US | disclosed |
| WO-2006070284-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006070284-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2005120514-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039764-B2 | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression | PDE4A, PDE7B, PDE2A | PDE10A 12/4885PDE3A 6/4885PDE3B 8/4885 |
| US-20060183763-A1 | Novel pyrrolidyl derivatives of heteroaromatic compounds | PDE12, PDE4A, PDE7A | PDE10A 9/4885PDE3A 10/4885PDE3B 16/4885 |
| US-20160143912-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | PDE4A, PDE7B, PDE2A | PDE10A 12/4885PDE3A 6/4885PDE3B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.